Usability of Andago V2.0 in Gait Rehabilitation of Stroke Patients
Single-center Usability Study of the Overground Gait and Balance Training Device Andago V2.0 in Patients With Gait Disorder After Stroke at a Center for Neurological Rehabilitation
1 other identifier
interventional
15
1 country
1
Brief Summary
Andago V2.0 is a recently developed overground gait and balance training device. Many patients in neurorehabilitation suffer from gait disorders, most typically after stroke. Since pharmacological therapies are basically not available, neurorehabilitation plays an important role in the treatment of such patients. The Andago V2.0 may represent a useful device in the rehabilitation of stroke and other neurological patients featuring a severe gait disorder. Therefore a study has been designed to investigate the usability of the Andago V2.0 in the setting of a neurorehabilitation clinic. The primary outcomes of this study are the usability and acceptance of the investigational medical device (IMD). Usability is mainly measured by the time spent for the set-up and release of the participant, achieved training times and distances, the number of stumbles, collisions and emergency stops and the error messages during the session. Besides patient and therapist satisfaction with the Andago V2.0 is recorded.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2016
CompletedFirst Submitted
Initial submission to the registry
March 15, 2016
CompletedFirst Posted
Study publicly available on registry
April 12, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 3, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 3, 2017
CompletedOctober 1, 2018
September 1, 2018
11 months
March 15, 2016
September 27, 2018
Conditions
Outcome Measures
Primary Outcomes (3)
Usability of the IMD according to the number of participants that are able to use the Andago V2.0
3 weeks
Acceptance of the IMD as measured by a therapist satisfaction questionnaire
3 weeks
Acceptance of the IMD as measured by a patient satisfaction questionnaire
3 weeks
Study Arms (1)
Treatment arm
EXPERIMENTALIn this arm the Andago V2.0 is used.
Interventions
The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
Eligibility Criteria
You may qualify if:
- Informed consent as documented by signature
- Primary diagnosis of cerebral infarction (ICD-10: I63.0-I63.9) or intracerebral haemorrhage (ICD-10: I61.0-I69.9) independent of its location, age or cause
- Gait disorder defined by a category of 1 to 3 on the Functional Ambulation Classification (FAC) (17)
- Age above 18 years
- Admission to Rehaklinik Zihlschlacht for in-patient neurorehabilitation
You may not qualify if:
- Inability of the participant to understand the informed consent or to follow the procedures of the study, e.g., due to language problems, psychiatric disorders, cognitive impairment or aphasia (item 9 of the National Institute of Health Stroke Scale (NIHSS) ≥2)
- Weight \>135 kg
- Height \>200 cm
- Bone fragility (e.g., non-consolidated fractures or osteotomies including craniotomies, osteopenia, osteoporosis or symptoms or indices in the patient history that infer a higher risk of bone density reduction)
- Unstable arthroplasty
- Uncontrolled knee or ankle instability that would still pose a danger despite the Body Weight Support (BWS) (especially lateral instability)
- Lack of head control
- Joint contractures
- Relevant differences in leg length
- Skin lesions (including pressure sores or enteric stomata) in areas of contact with harness support or lower extremity loading (feet)
- Relevant sensory impairment in the lower limbs and trunk, especially with reduced pain sensation
- Recent history or significant risk of seizures
- Relevant cardiovascular conditions, e.g., cardiac insufficiency and thoracotomy, uncontrolled orthostatic hypotension or other circulatory problems, vascular disorders of the lower limbs
- Mechanical ventilation
- Long-term infusions (e.g., baclofen pump, other intrathecal pumps)
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rehaklinik Zihlschlacht, Center for Neurological Rehabilitation
Zihlschlacht, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Detlef Marks
Rehaklinik Zihlschlacht
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 15, 2016
First Posted
April 12, 2016
Study Start
March 1, 2016
Primary Completion
February 3, 2017
Study Completion
February 3, 2017
Last Updated
October 1, 2018
Record last verified: 2018-09
Data Sharing
- IPD Sharing
- Will not share